Seven Eight Capital’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-20,729
| Closed | -$2.38M | – | 428 |
|
|
2024
Q3 | $2.38M | Buy |
20,729
+7,082
| +52% | +$804K | 0.21% | 143 |
|
|
2024
Q2 | $1.45M | Buy |
13,647
+9,509
| +230% | +$955K | 0.15% | 232 |
|
|
2024
Q1 | $400K | Buy |
+4,138
| New | +$424K | 0.04% | 492 |
|
|
2023
Q4 | – | Sell |
-3,577
| Closed | -$364K | – | 777 |
|
|
2023
Q3 | $364K | Buy |
+3,577
| New | +$363K | 0.04% | 455 |
|
|
2023
Q2 | – | Sell |
-57,388
| Closed | -$5.28M | – | 602 |
|
|
2023
Q1 | $5.28M | Buy |
+57,388
| New | +$5.01M | 1.1% | 8 |
|
|
2022
Q3 | – | Sell |
-9,499
| Closed | -$803K | – | 581 |
|
|
2022
Q2 | $803K | Buy |
+9,499
| New | +$833K | 0.32% | 112 |
|
|
2021
Q4 | – | Sell |
-11,701
| Closed | -$957K | – | 612 |
|
|
2021
Q3 | $957K | Sell |
11,701
-7,696
| -40% | -$692K | 0.09% | 316 |
|
|
2021
Q2 | $1.77M | Buy |
+19,397
| New | +$1.73M | 0.25% | 126 |
|
|
2020
Q4 | – | Sell |
-26,987
| Closed | -$2.35M | – | 560 |
|
|
2020
Q3 | $2.35M | Buy |
26,987
+24,387
| +938% | +$2.11M | 0.51% | 17 |
|
|
2020
Q2 | $227K | Buy |
+2,600
| New | +$224K | 0.17% | 248 |
|
|
2018
Q3 | – | Sell |
-51,633
| Closed | -$3.5M | – | 662 |
|
|
2018
Q2 | $3.5M | Buy |
+51,633
| New | +$3.56M | 0.24% | 129 |
|
|
2017
Q4 | – | Sell |
-14,693
| Closed | -$1.13M | – | 536 |
|
|
2017
Q3 | $1.13M | Buy |
14,693
+10,937
| +291% | +$826K | 0.14% | 236 |
|
|
2017
Q2 | $281K | Buy |
+3,756
| New | +$266K | 0.04% | 361 |
|
|
2017
Q1 | – | Sell |
-2,306
| Closed | -$150K | – | 631 |
|
|
2016
Q4 | $150K | Buy |
+2,306
| New | +$150K | 0.03% | 427 |
|
|
2016
Q3 | – | Sell |
-1,078
| Closed | -$80K | – | 485 |
|
|
2016
Q2 | $80K | Buy |
+1,078
| New | +$74.5K | 0.03% | 414 |
|
|
2016
Q1 | – | Sell |
-1,190
| Closed | -$92K | – | 642 |
|
|
2015
Q4 | $92K | Buy |
+1,190
| New | +$94.5K | 0.06% | 356 |
|
|
2014
Q4 | – | Sell |
-5,803
| Closed | -$489K | – | 601 |
|
|
2014
Q3 | $489K | Buy |
5,803
+3,571
| +160% | +$289K | 0.38% | 77 |
|
|
2014
Q2 | $181K | Buy |
+2,232
| New | +$176K | 0.17% | 197 |
|
|
2014
Q1 | – | Sell |
-670
| Closed | -$48K | – | 436 |
|
|
2013
Q4 | $48K | Buy |
+670
| New | +$46.6K | 0.05% | 409 |
|
Other funds holding NVS
Seven Eight Capital's NVS Position: Q4 2024 in Review
Seven Eight Capital sold out of Novartis (NVS) in Q4 2024, closing a stake of 20,729 shares — an estimated $2.38M sold.
Seven Eight Capital first reported a position in NVS in Q4 2013 and held it in 19 quarters. The position peaked at $5.28M in Q1 2023. 1,341 funds tracked by Wall St. Rank hold NVS as of Q4 2024.
- Seven Eight Capital reported no remaining Novartis position as of Q4 2024 after selling out during the quarter.
- Seven Eight Capital sold 20,729 Novartis shares in Q4 2024, an estimated $2.38M.
- Seven Eight Capital first reported a position in Novartis in Q4 2013 and held it in 19 quarters.
- Seven Eight Capital's Novartis position peaked at $5.28M in Q1 2023.
- 1,341 funds tracked by Wall St. Rank held Novartis as of Q4 2024.
Based on Seven Eight Capital's 13F filing for Q4 2024.